Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.
Details
News Market Reaction – CHRS
On Feb 23, the day this news came out, CHRS closed 0.61% below the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
- 46th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Daylight Time
- Citizens Life Sciences Conference in Miami, on Tuesday, March 10, 2026, at 2:50 p.m. Eastern Daylight Time
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.